Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma

Nature Communications

Volumn 6, Issue , 2015, Pages

  Swaminathan, Bhairavi ^a   Thorleifsson, Gudmar ^b   Jöud, Magnus ^a,c   Ali, Mina ^a   Johnsson, Ellinor ^a   Ajore, Ram ^a   Sulem, Patrick ^b   Halvarsson, Britt Marie ^a   Eyjolfsson, Gudmundur ^d   Haraldsdottir, Vilhelmina ^e   Hultman, Christina ^f   Ingelsson, Erik ^g   Kristinsson, Sigurdur Y ^h   Kähler, Anna K ^f   Lenhoff, Stig ⁱ   Masson, Gisli ^b   Mellqvist, Ulf Henrik ^j   Månsson, Robert ^f   Nelander, Sven ^k   Olafsson, Isleifur ^e   Sigurdardottir, Olof ^l   Steingrimsdóttir, Hlif ^e   Vangsted, Annette ^m   Vogel, Ulla ⁿ   Waage, Anders ^o   Nahi, Hareth ^f   Gudbjartsson, Daniel F ^b   Rafnar, Thorunn ^b   Turesson, Ingemar ⁱ   Gullberg, Urban ^a   Stefánsson, Kári ^b   Hansson, Markus ^a,i   Thorsteinsdóttir, Unnur ^b   Nilsson, Björn ^a,c,p   more..

^a LUND UNIVERSITY   (Sweden)

^b DECODE GENETICS   (Iceland)

^c Diaverum Renal Services Group   (Sweden)

^d Laboratory in Mjodd   (Iceland)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

^h UNIVERSITY OF ICELAND   (Iceland)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^k UPPSALA UNIVERSITY   (Sweden)

^l Akureyri Hospital   (Iceland)

^m Mental Health Services CPH   (Denmark)

ⁿ NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^o NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^p BROAD INSTITUTE OF MIT AND HARVARD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MESSENGER RNA; ELL2 PROTEIN, HUMAN; PROTEIN; TOM1 PROTEIN, HUMAN; TRANSCRIPTION ELONGATION FACTOR;

ALLELE; ANTIBODY; BACTERIAL DISEASE; BLOOD; CANCER; CLONAL GROWTH; GENE EXPRESSION; GENETIC ANALYSIS; HEALTH RISK;

ARTICLE; BACTERIAL MENINGITIS; CANCER RISK; CONTROLLED STUDY; DNA SEQUENCE; ELL2 GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL; PROTEIN BLOOD LEVEL; QUANTITATIVE TRAIT; RNA PROCESSING; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STOICHIOMETRY; TRANSCRIPTION ELONGATION; TRANSCRIPTION REGULATION; BLOOD; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; META ANALYSIS; MULTICENTER STUDY;

BACTERIA (MICROORGANISMS);

GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MENINGITIS, BACTERIAL; MULTIPLE MYELOMA; PROTEINS; TRANSCRIPTIONAL ELONGATION FACTORS;

EID: 84930226491     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8213     Document Type: Article

References (52)

1. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538-e548 (2014).
2. Laubach, J., Richardson, P. & Anderson, K. Multiple myeloma. Annu. Rev. Med. 62, 249-264 (2011).
3. Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418-5422 (2009).
4. Kristinsson, S. Y. et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 94, 1714-1720 (2009).
5. Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362-1369 (2006).
6. Lynch, H. T., Sanger, W. G., Pirruccello, S., Quinn-Laquer, B. & Weisenburger, D. D. Familial multiple myeloma: a family study and review of the literature. J. Natl Cancer Inst. 93, 1479-1483 (2001).
7. Lynch, H. T. et al. Familial myeloma. N. Engl. J. Med. 359, 152-157 (2008).
8. Kristinsson, S. Y. et al. Patterns of hematologic malignancies and solid tumors among 37, 838 first-degree relatives of 13, 896 patients with multiple myeloma in Sweden. Int. J. Cancer 125, 2147-2150 (2009).
9. Landgren, O. et al. Risk of plasma cell and lymphoproliferative disorders among 14 621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114, 791-795 (2009).
10. Altieri, A., Chen, B., Bermejo, J. L., Castro, F. & Hemminki, K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer 42, 1661-1670 (2006).
11. Morgan, G. J. et al. Inherited genetic susceptibility to multiple myeloma. Leukemia 28, 518-524 (2014).
12. Vachon, C. M. et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 114, 785-790 (2009).
13. Weinhold, N. et al. The CCND1 c.870G4A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat. Genet. 45, 522-525 (2013).
14. Broderick, P. et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat. Genet. 44, 58-61 (2012).
15. Chubb, D. et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat. Genet. 45, 1221-1225 (2013).
16. Styrkarsdottir, U. et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature 497, 517-520 (2013).
17. Kong, A. et al. Detection of sharing by descent, long-range phasing and haplotype imputation. Nat. Genet. 40, 1068-1075 (2008).
18. Kong, A. et al. Parental origin of sequence variants associated with complex diseases. Nature 462, 868-874 (2009).
19. Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412-5417 (2009).
20. Liu, M., Hsu, J., Chan, C., Li, Z. & Zhou, Q. The ubiquitin ligase Siah1 controls ELL2 stability and formation of super elongation complexes to modulate gene transcription. Mol. Cell 46, 325-334 (2012).
21. Luo, Z., Lin, C. & Shilatifard, A. The super elongation complex (SEC) family in transcriptional control. Nat. Rev. Mol. Cell Biol. 13, 543-547 (2012).
22. Benson, M. J. et al. Heterogeneous nuclear ribonucleoprotein L-like (hnRNPLL) and elongation factor, RNA polymerase II, 2 (ELL2) are regulators ofmRNA processing in plasma cells. Proc. Natl Acad. Sci. USA 109, 16252-16257 (2012).
23. Santos, P., Arumemi, F., Park, K. S., Borghesi, L. & Milcarek, C. Transcriptional and epigenetic regulation of B cell development. Immunol. Res. 50, 105-112 (2011).
24. Martincic, K., Alkan, S. A., Cheatle, A., Borghesi, L. & Milcarek, C. Transcription elongation factor ELL2 directs immunoglobulin secretion in plasma cells by stimulating altered RNA processing. Nat. Immunol. 10, 1102-1109 (2009).
25. Shell, S. A., Martincic, K., Tran, J. & Milcarek, C. Increased phosphorylation of the carboxyl-terminal domain of RNA polymerase II and loading of polyadenylation and cotranscriptional factors contribute to regulation of the Ig heavy chain mRNA in plasma cells. J. Immunol. 179, 7663-7673 (2007).
26. Park, K. S. et al. transcription elongation factor ELL2 drives Ig secretoryspecific mRNA production and the unfolded protein response. J. Immunol. 193, 4663-4674 (2014).
27. Benson, M. J. et al. Heterogeneous nuclear ribonucleoprotein L-like (hnRNPLL) and elongation factor, RNA polymerase II, 2 (ELL2) are regulators of mRNA processing in plasma cells. Proc. Natl Acad. Sci. USA 109, 16252-16257 (2012).
28. Fowler, T. et al. Regulation of MYC expression and differential JQ1 sensitivity in cancer cells. PloS ONE 9, e87003 (2014).
29. Shilatifard, A. et al. ELL2, a new member of an ELL family of RNA polymerase II elongation factors. Proc. Natl Acad. Sci. USA 94, 3639-3643 (1997).
30. Franceschini, N. et al. Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am. J. Hum. Genet. 91, 744-753 (2012).
31. Ripke, S. et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 45, 1150-1159 (2013).
32. Anderson, C. A., Pettersson, F. H., Clarke, G. M., Cardon, L. R., Morris, A. P. & Zondervan, K. T. Data quality control in genetic case-control association studies. Nat. Protoc. 5, 1564-1573 (2010).
33. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
34. Consortium TGP. An integrated map of genetic variation from 1, 092 human genomes. Nature 491, 56-65 (2012).
35. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 997-1004 (1999).
36. Delaneau, O., Zagury, J. F. & Marchini, J. Improved whole-chromosome phasing for disease and population genetic studies. Nat. Methods 10, 5-6 (2013).
37. Howie, B. N., Donelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
38. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. Nat. Rev. Genet. 11, 499-511 (2010).
39. Gudbjartsson, D. F. et al. Large-scale whole-genome sequencing of the Icelandic population. Nat. Genet. 47, 435-444 (2015).
40. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
41. McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P. & Cunningham, F. Deriving the consequences of genomic variants with the Ensembl API and SNP effect predictor. Bioinformatics 26, 2069-2070 (2010).
42. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190-2191 (2010).
43. Novershtern, N. et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144, 296-309 (2011).
44. Boyd, K. D. et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin. Cancer Res. 17, 7776-7784 (2011).
45. Broyl, A. et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116, 2543-2553 (2010).
46. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
47. Zhan, F. et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109, 1692-1700 (2007).
48. Gretarsdottir, S. et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet. 35, 131-138 (2003).
49. Emilsson, V. et al. Genetics of gene expression and its effect on disease. Nature 452, 423-428 (2008).
50. Westra, H. J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45, 1238-1243 (2013).
51. Consortium TIH. Integrating common and rare genetic variation in diverse human populations. Nature 467, 52-58 (2010).
52. Lappalainen, T. et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501, 506-511 (2013).